加速批准与肿瘤药物研发时间表。 - Suppr

Suppr

超能文献

Accelerated approval and oncology drug development timelines.

作者信息

Lanthier Michael L, Sridhara Rajeshwari, Johnson John R, Farrell Ann, Keegan Patricia, Justice Robert, Pazdur Richard

出版信息

J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1.

DOI:10.1200/JCO.2009.26.2121

PMID:20194846

Abstract

摘要

相似文献

Accelerated approval and oncology drug development timelines.

J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1.

Accelerated approval of oncology products: the food and drug administration experience.

J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.

Accelerated approval of oncology drugs: can we do better?

J Natl Cancer Inst. 2011 Apr 20;103(8):616-7. doi: 10.1093/jnci/djr104. Epub 2011 Mar 21.

Accelerated approval of oncology products: a decade of experience.

J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. doi: 10.1093/jnci/djh279.

Accelerated approval seen as triumph and roadblock for cancer drugs.

J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6. doi: 10.1093/jnci/96.20.1495.

The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.

Oncologist. 2010;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13.

Communicating with the FDA: the "third rail" of a new model for drug development.

J Clin Pharmacol. 2008 Feb;48(2):144-5. doi: 10.1177/0091270007313560.

They are from the government and they really are here to help you.

J Clin Pharmacol. 2008 Feb;48(2):142-3. doi: 10.1177/0091270007313559.

The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.

Expert Rev Anticancer Ther. 2005 Apr;5(2):197-200. doi: 10.1586/14737140.5.2.197.

Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.

Epilepsy Res Suppl. 1993;10:31-44.

引用本文的文献

Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.

Expert Opin Investig Drugs. 2018 Feb;27(2):155-162. doi: 10.1080/13543784.2018.1430137. Epub 2018 Jan 22.

Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Oncologist. 2013;18(1):104-11. doi: 10.1634/theoncologist.2012-0235. Epub 2012 Dec 20.

Can cancer clinical trials be fixed?

Nat Biotechnol. 2011 Jan;29(1):13-5. doi: 10.1038/nbt.1746.

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Blood. 2010 Oct 7;116(14):2420-8. doi: 10.1182/blood-2010-05-285387. Epub 2010 Jun 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Accelerated approval and oncology drug development timelines.

J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1.

Accelerated approval of oncology products: the food and drug administration experience.

J Natl Cancer Inst. 2011 Apr 20;103(8):636-44. doi: 10.1093/jnci/djr062. Epub 2011 Mar 21.

Accelerated approval of oncology drugs: can we do better?

J Natl Cancer Inst. 2011 Apr 20;103(8):616-7. doi: 10.1093/jnci/djr104. Epub 2011 Mar 21.

Accelerated approval of oncology products: a decade of experience.

J Natl Cancer Inst. 2004 Oct 20;96(20):1500-9. doi: 10.1093/jnci/djh279.

Accelerated approval seen as triumph and roadblock for cancer drugs.

J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6. doi: 10.1093/jnci/96.20.1495.

The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.

Oncologist. 2010;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13.

Communicating with the FDA: the "third rail" of a new model for drug development.

J Clin Pharmacol. 2008 Feb;48(2):144-5. doi: 10.1177/0091270007313560.

They are from the government and they really are here to help you.

J Clin Pharmacol. 2008 Feb;48(2):142-3. doi: 10.1177/0091270007313559.

The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.

Expert Rev Anticancer Ther. 2005 Apr;5(2):197-200. doi: 10.1586/14737140.5.2.197.

Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.

Epilepsy Res Suppl. 1993;10:31-44.

引用本文的文献

Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.

Expert Opin Investig Drugs. 2018 Feb;27(2):155-162. doi: 10.1080/13543784.2018.1430137. Epub 2018 Jan 22.

Oncology drug development and approval of systemic anticancer therapy by the U.S. Food and Drug Administration.

Oncologist. 2013;18(1):104-11. doi: 10.1634/theoncologist.2012-0235. Epub 2012 Dec 20.

Can cancer clinical trials be fixed?

Nat Biotechnol. 2011 Jan;29(1):13-5. doi: 10.1038/nbt.1746.

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Blood. 2010 Oct 7;116(14):2420-8. doi: 10.1182/blood-2010-05-285387. Epub 2010 Jun 10.